168 related articles for article (PubMed ID: 36252108)
1. Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era.
Warner AL; Lu L; Ghaznavi Z; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008936. PubMed ID: 36252108
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
[TBL] [Abstract][Full Text] [Related]
3. Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.
Mukhopadhyay A; Reynolds HR; Nagler AR; Phillips LM; Horwitz LI; Katz SD; Blecker S
BMC Cardiovasc Disord; 2022 Aug; 22(1):354. PubMed ID: 35927632
[TBL] [Abstract][Full Text] [Related]
4. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
Ezekowitz JA; McMullan CJ; Westerhout CM; Piña IL; Lopez-Sendon J; Anstrom KJ; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Koglin J; Armstrong PW; Butler J;
Circ Heart Fail; 2023 Sep; 16(9):e010599. PubMed ID: 37417824
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
Yan BW; Spahillari A; Pandya A
Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
[TBL] [Abstract][Full Text] [Related]
6. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ
J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107
[TBL] [Abstract][Full Text] [Related]
7. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
8. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
[TBL] [Abstract][Full Text] [Related]
11. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction.
Tran JS; Loveland MG; Alamer A; Piña IL; Sweitzer NK
Circ Heart Fail; 2022 Nov; 15(11):e009395. PubMed ID: 36378759
[TBL] [Abstract][Full Text] [Related]
13. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.
Park DY; An S; Attanasio S; Jolly N; Malhotra S; Doukky R; Samsky MD; Sen S; Ahmad T; Nanna MG; Vij A
Am J Cardiol; 2023 Jan; 187():84-92. PubMed ID: 36459752
[TBL] [Abstract][Full Text] [Related]
14. Validity of Performance and Outcome Measures for Heart Failure.
Patel J; Sandhu A; Parizo J; Moayedi Y; Fonarow GC; Heidenreich PA
Circ Heart Fail; 2018 Sep; 11(9):e005035. PubMed ID: 30354367
[TBL] [Abstract][Full Text] [Related]
15. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
16. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
18. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
[TBL] [Abstract][Full Text] [Related]
19. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.
Kashiwagi Y; Nagoshi T; Kimura H; Tanaka Y; Oi Y; Inoue Y; Ogawa K; Kawai M; Yoshimura M
ESC Heart Fail; 2023 Jun; 10(3):1860-1870. PubMed ID: 36942494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
